drugset
Drugs / Sulesomab
last change Oct 2018 re-read 3 minutes ago

Sulesomab

also known as IMMU-MN-3 · Leukoscan · Technetium (99mtc) sulesomab

Monoclonal antibody

Investigated by
Hospices Civils de Lyon

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Withdrawn EU (EMA) LeukoScan — 2018-01-30 europa.eu ↗
Approved EU (EMA) LeukoScan — 1997-02-14 europa.eu ↗

Trials 1

today
EU approved 1997
NCT03112356 · Ph 4
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT03112356 Jun 2017 → Oct 2018 endocarditis Hospices Civils de Lyon Unknown No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Sulesomab “An alternative method is to label leukocytes in vivo with an anti-murin anti body fragment ( Sulesomab , Leukoscan®).” NCT03112356 ↗
Known as IMMU-MN-3 ChEMBL registry synonym — accepted as the source's own label CHEMBL2108809 ↗
Known as Leukoscan “An alternative method is to label leukocytes in vivo with an anti-murin anti body fragment ( Sulesomab , Leukoscan®).” NCT03112356 ↗
Known as Technetium (99mtc) sulesomab ChEMBL registry synonym — accepted as the source's own label CHEMBL2108809 ↗
Modality Monoclonal antibody — CHEMBL2108809 ↗
Route Intravenous “after infusion of 99mTc-Leukoscan (1000 MBq)” NCT03112356 ↗